Literature DB >> 18029283

Ovarian suppression treatment prior to in-vitro fertilization and embryo transfer in Chinese women with stage III or IV endometriosis.

Caihong Ma1, Jie Qiao, Ping Liu, Guian Chen.   

Abstract

OBJECTIVE: To evaluate the efficacy of a 2-month treatment with a gonadotropin-releasing hormone (GnRH) agonist prior to in-vitro fertilization in Chinese women with moderate or severe endometriosis.
METHODS: A study of 162 women surgically diagnosed as having moderate or severe endometriosis. Pituitary down-regulation was achieved with injections of a GnRH agonist prior to the IVF procedures either for 7 to 10 days in the mid-luteal phase (group 1 [standard protocol], 97 cycles in total), or for 2 months (group 2, 55 cycles), or 3 months (group 3, 75 cycles).
RESULTS: Women pretreated with a GnRH agonist for 2 or 3 months required significantly higher doses of gonadotropin for ovarian stimulation (P<0.001), and for a longer time, than those treated with the standard long protocol (P<0.05). The number of oocytes and good embryos was lower in group 3 than in groups 1 or 2 (P<0.05). The implantation rate was significantly higher in group 2 than in group 1 (P<0.02).
CONCLUSION: A 2-month treatment with a GnRH agonist prior to IVF produced a trend toward an increase in the implantation rate in a group of Chinese women with stages III and IV endometriosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029283     DOI: 10.1016/j.ijgo.2007.08.021

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  7 in total

1.  Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.

Authors:  Sharif Sakr; Hanyia Naqvi; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2014-01-31       Impact factor: 4.736

2.  Progestin-Primed Ovarian Stimulation Protocol for Patients With Endometrioma.

Authors:  Ai-Min Yang; Teng-Fei Feng; Yan Han; Zhi-Ming Zhao; Wei Wang; Yi-Zhuo Wang; Xiao-Qi Zuo; Xiuhua Xu; Bao-Jun Shi; Lipeng Li; Gui-Min Hao; Na Cui
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

Review 3.  A review of the risk factors, genetics and treatment of endometriosis in Chinese women: a comparative update.

Authors:  Yi Dai; Xiaoyan Li; Jinghua Shi; Jinhua Leng
Journal:  Reprod Health       Date:  2018-05-21       Impact factor: 3.223

Review 4.  Continuous oral contraceptives versus long-term pituitary desensitization prior to IVF/ICSI in moderate to severe endometriosis: study protocol of a non-inferiority randomized controlled trial.

Authors:  L E E van der Houwen; M C I Lier; A M F Schreurs; M van Wely; P G A Hompes; A E P Cantineau; R Schats; C B Lambalk; V Mijatovic
Journal:  Hum Reprod Open       Date:  2019-02-23

5.  Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis.

Authors:  Ektoras X Georgiou; Pedro Melo; Philip E Baker; Hassan N Sallam; Aydin Arici; Juan A Garcia-Velasco; Ahmed M Abou-Setta; Christian Becker; Ingrid E Granne
Journal:  Cochrane Database Syst Rev       Date:  2019-11-20

6.  Elevated Levels of Monocyte Chemotactic Protein-1 in the Follicular Fluid Reveals Different Populations among Women with Severe Endometriosis.

Authors:  Pierre-Emmanuel Bouet; Juan-Manuel Chao de la Barca; Lisa Boucret; Philippe Descamps; Guillaume Legendre; Hady El Hachem; Simon Blanchard; Pascale Jeannin; Pascal Reynier; Pascale May-Panloup
Journal:  J Clin Med       Date:  2020-05-01       Impact factor: 4.241

7.  The effectiveness of different down-regulating protocols on in vitro fertilization-embryo transfer in endometriosis: a meta-analysis.

Authors:  Xue Cao; Hong-Yang Chang; Jun-Yan Xu; Yi Zheng; Yun-Gai Xiang; Bing Xiao; Xu-Jing Geng; Li-Li Ni; Xi-Ying Chu; Shi-Bo Tao; Yan He; Gen-Hong Mao
Journal:  Reprod Biol Endocrinol       Date:  2020-02-29       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.